Michael Heffernan
Founder and Chairman
Michael Heffernan is the Founder and Chairman of the Board of Collegium Pharmaceutical. Mr. Heffernan served as President and Chief Executive Officer (CEO) of Collegium Pharmaceutical until June 2018. He is a successful entrepreneur and biopharmaceutical leader with over 25 years of experience building and leading development stage and commercial companies.
Read more
Rita Balice-Gordon, Ph.D.
Rita Balice-Gordon, Ph.D., has served as the Chief Scientific Officer of Muna Therapeutics, a newly formed biotech company focused on developing novel therapeutics for patients with neurodegenerative diseases, since May 2020, and is an entrepreneur-in-residence at Novo Seeds since August 2020. Previously, Dr. Balice-Gordon served in scientific roles of increasing responsibility at Sanofi, Inc., most recently as Global Head of Rare and Neurological Diseases. Read more
Garen Bohlin
Garen Bohlin held senior executive positions with biotechnology companies for almost 30 years. In his final operating role, Mr. Bohlin was Executive Vice President of Constellation Pharmaceuticals. Previously, he served as Chief Operating Officer of Sirtris Pharmaceuticals (acquired by GlaxoSmithKline). Prior to Sirtris, he was President and Chief Executive Officer of Syntonix Pharmaceuticals (acquired by Biogen).
Read more
Joe Ciaffoni
President and CEO
Joe Ciaffoni was appointed President and Chief Executive Officer of Collegium Pharmaceutical in July 2018. Mr. Ciaffoni joined Collegium Pharmaceutical in May 2017 as Executive Vice President and Chief Operating Officer. Prior to joining Collegium, he served as President, U.S. Branded Pharmaceuticals of Endo International plc. Read more
John A. Fallon, M.D.
Dr. John Fallon served as Senior Vice President and Chief Physician Executive at Blue Cross Blue Shield of Massachusetts (BCBS) from 2004 through 2015. Prior to his role at BCBS, Dr. Fallon served as Chief Executive Officer (CEO) for clinical affairs at the State University of New York Downstate Medical Center. His professional experience includes the Partners Healthcare System, where he was Chairman of the physician network.
Read more
John G. Freund, M.D.
Dr. John G. Freund co-founded Skyline Ventures in 1997 and has served as a Partner at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, a private capital investment firm. Previously, he co-founded Intuitive Surgical, a medical device company, and served on its Board of Directors.
Read more
Gwen A. Melincoff
Gwen Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Ms. Melincoff is currently Managing Director at Gemini Advisors LLC and an advisor to Phase 1 Ventures and Verge Genomics. Previously, she served as Vice President of Business Development at BTG International Inc., a UK-specialist healthcare company.
Read more
Gino Santini
Gino Santini is a senior advisor providing financing and business consulting services to venture capital, pharmaceutical and biotech companies. He currently serves as Chairman of the board of directors of AMAG Pharmaceuticals Inc. (AMAG), and as a member of the board of directors of Allena Pharmaceuticals, Inc. (ALNA), Intercept Pharmaceuticals, Inc. (ICPT) and Horizon Pharma plc (HZNP), as well as several privately held companies.
Read more
Ted Schroeder
Ted Schroeder is CEO, and Director of Nabriva Therapeutics, Inc. Previously, Mr. Schroeder co-founded Zavante Pharmaceuticals, Inc. where he was President and CEO and Director until its acquisition by Nabriva in July 2018.
Read more